Advances in molecular imaging of immune checkpoint targets in malignancies: current and future prospect

Liposomal nanohybrid cerasomes targeted to PD-L1 enable dual-modality imaging and improve antitumor treatments

(2018) Yang Du et al.   CANCER LETTERS

In Vivo Imaging of the Programmed Death Ligand 1 by18F PET

(2017) Dinko E. González Trotter et al.   JOURNAL OF NUCLEAR MEDICINE

Synthesis and Biologic Evaluation of a Novel18F-Labeled Adnectin as a PET Radioligand for Imaging PD-L1 Expression

(2017) David J. Donnelly et al.   JOURNAL OF NUCLEAR MEDICINE

Nuclear and Fluorescent Labeled PD-1-Liposome-DOX-64Cu/IRDye800CW Allows Improved Breast Tumor Targeted Imaging and Therapy

(2017) Yang Du et al.   MOLECULAR PHARMACEUTICS

ImmunoPET Imaging of CTLA-4 Expression in Mouse Models of Non-small Cell Lung Cancer

(2017) Emily B. Ehlerding et al.   MOLECULAR PHARMACEUTICS

PD-L1 Detection in Tumors Using [64Cu]Atezolizumab with PET

(2016) Wojciech G. Lesniak et al.   BIOCONJUGATE CHEMISTRY

Checkpoint Inhibitors and Their Application in Breast Cancer

(2016) Davide Bedognetti et al.   Breast Care

Molecular Imaging of Immunotherapy Targets in Cancer

(2016) E. B. Ehlerding et al.   JOURNAL OF NUCLEAR MEDICINE

Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging

(2016) Aaron T. Mayer et al.   JOURNAL OF NUCLEAR MEDICINE

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

(2016) Weiping Zou et al.   Science Translational Medicine

A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors

(2016) Samit Chatterjee et al.   Oncotarget

High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers

(2016) Michael Hettich et al.   Theranostics

Novel Radiotracer for ImmunoPET Imaging of PD-1 Checkpoint Expression on Tumor Infiltrating Lymphocytes

(2015) Arutselvan Natarajan et al.   BIOCONJUGATE CHEMISTRY

Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti-PD-L1 Antibodies

(2015) S. Heskamp et al.   CANCER RESEARCH

Cancer Immunotherapy: A Future Paradigm Shift in the Treatment of Non-Small Cell Lung Cancer

(2015) V. K. Anagnostou et al.   CLINICAL CANCER RESEARCH

Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma

(2015) Yuki Katsuya et al.   LUNG CANCER

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging

(2015) Roy L. Maute et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway

(2015) Kim C. Ohaegbulam et al.   TRENDS IN MOLECULAR MEDICINE

T cell-NF-κB activation is required for tumor control in vivo

(2015) Sarah E Barnes et al.   Journal for ImmunoTherapy of Cancer

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

64Cu-DOTA-Anti-CTLA-4 mAb Enabled PET Visualization of CTLA-4 on the T-Cell Infiltrating Tumor Tissues

(2014) Kei Higashikawa et al.   PLoS One

Zirconium-89 Labeled Antibodies: A New Tool for Molecular Imaging in Cancer Patients

(2014) Floor C. J. van de Watering et al.   Biomed Research International

PD-L1 Expression in Triple-Negative Breast Cancer

(2014) E. A. Mittendorf et al.   Cancer Immunology Research

The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer

(2013) S. Muenst et al.   BREAST CANCER RESEARCH AND TREATMENT

Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

(2013) David R. Spigel et al.   JOURNAL OF CLINICAL ONCOLOGY

New checkpoint inhibitors ride the immunotherapy tsunami

(2013) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

A Molecular Imaging Primer: Modalities, Imaging Agents, and Applications

(2012) Michelle L. James et al.   PHYSIOLOGICAL REVIEWS